Multi-center, Open-label, Dose Escalation, Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2017
At a glance
- Drugs INO 8000 (Primary) ; INO 8000 (Primary)
- Indications Hepatitis C
- Focus Adverse reactions
- Sponsors GeneOne Life Science
- 04 Aug 2017 Status changed from active, no longer recruiting to completed.
- 07 Nov 2016 Planned End Date changed from 1 Oct 2016 to 1 Feb 2017.
- 09 Aug 2016 Planned End Date changed from 1 Jun 2016 to 1 Oct 2016.